Skip to main
JNJ
JNJ logo

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 29 analyst ratings
Buy
Strong Buy 31%
Buy 21%
Hold 48%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson has demonstrated a significant acceleration in revenue growth, moving from 3-4% between 2016 and 2019 to 6.1% in 2022 and further to 7.8% in 2023, underpinned by innovation and a focused approach to its pharmaceutical and medical device divisions. The company's promising product pipeline, particularly with advancements in therapies such as Tremfya, Erleada, and Spravato, positions it favorably for continued momentum in revenue generation and market recognition. Furthermore, JNJ is seen as attractively valued, maintaining historical multiples while benefiting from a strengthened financial profile following the divestment of its consumer business in 2023.

Bears say

Johnson & Johnson's stock outlook is negatively impacted by anticipated challenges in organic revenue growth, specifically due to a potential decline in contributions from its pharmaceutical pipeline and lost exclusivity for key drugs, which could limit revenues to below $57 billion by 2025. The company faces competitive pressures in its MedTech division that may hinder growth, in addition to the risks associated with mergers and acquisitions, ongoing litigation costs, and regulatory pressures from the Inflation Reduction Act and state-level prescription drug boards. Overall, these factors collectively contribute to a forecast of weaker financial performance and uncertainties surrounding future revenue stability.

JNJ has been analyzed by 29 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 21% recommend Buy, 48% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 29 analysts, JNJ has a Buy consensus rating as of Aug 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $160.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $160.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.